sociated with mental status disorder (delirium or abulia; OR = 4.59; 95% CI = 1.41-14.89) and negatively associated with headache (OR = 0.03; 95% CI = 0.00-0.32). Presentation as isolated intracranial hypertension was associated with admission delay of more than 4 days (OR = 2.63; 95% CI = 0.97-7.14). Papilloedema was associated with an admission delay of more than 13 days (OR = 4.69; 95% CI = 1.61-13.61). There was no association between admission delay and the proportion of anticoagulated patients. The interval between onset of symptoms and start of anticoagulation was shorter in patients admitted earlier (p = 0.0001, for either admission within 24 h, 4 or 13 days). There is a considerable delay until the clinical picture associated with CVT is recognised as justifying hospital admission, especially when patients present with symptoms identical to isolated intracranial hypertension syndrome.
complicate its recognition and delay clinical suspicion and diagnosis. On the other hand CVT can be readily diagnosed using modern neuroimaging techniques, either MRI/MR venography or CT venography. Intravenous or subcutaneous anticoagulation improve the prognosis of acute CVT [11] . Local thrombolysis is selectively used in experienced centres in severe cases [12] . The clinical course of CVT is often unpredictable and in many patients the clinical picture worsens after diagnosis [13] . Delay in hospital admission and of CVT diagnosis postpones appropriate treatment.
The purpose of this study was twofold: (1) to describe the delay between the onset of symptoms and hospital admission of patients with CVT, and (2) to identify the variables that infl uence that delay, i.e. to test the hypothesis that more severe clinical presentation patterns have a shorter admission delay.
Method
We registered the interval (days) between the onset of symptoms and hospital admission in 91 consecutive patients admitted to 20 Portuguese hospitals between June 1995 and June 1998 (all patients were also included in the VENOPORT study [14] ). All cases were confi rmed by intra-arterial or MRI/MR venography or angiography.
Possible explanatory variables of the admission delay included were centre, age and gender, location of the occluded sinus/vein, parenchymal lesion on admission CT/MRI (infarct/oedema and haemorrhage), symptoms and signs at admission, presentation syndromes (isolated intracranial hypertension, defi ned as any combination of headache, vomiting and papilloedema with or without VI nerve palsy vs. other presentation syndromes) and risk factors for CVT.
We analysed the impact of admission delay on the prescription of anticoagulants and the number of days elapsed between the onset of symptoms and start of anticoagulation and between admission and start of anticoagulation. Outcome was assessed with the modifi ed Rankin Scale (mRS) [15] at hospital discharge (median 18 days) and at the end of follow-up (median 22 months; range 3-36 months) [16] . Unfavourable outcome was defi ned as an mRS 3-6.
Statistics
We dichotomised admission delay according to the median of the distribution. A second subgroup division contrasted the quartiles with the shortest admission delays (ultra-early admission) with those of the remaining patients, and the quartile with the longest (delayed) admission delays with those of the remaining patients. 
Results
Data on admission delay was available for 90 patients. Distribution of admission delay is shown in fi gure 1 . As expected the distribution was skewed, with a median of 4 days. Twenty-two (25%) patients were admitted within 24 h and 75% within 13 days. Two thirds of the patients were admitted within 7 days.
Variables positively and negatively correlated in bivariate analysis with an admission delay of 1 day or less (ultra-early admissions), 4 days or less, and 13 days (de- layed admissions are shown in table 1 ). There was no association between admission delay and centre, location of the occluded sinus/vein, and risk factors for CVT. In logistic regression analysis, admission within 24 h was positively associated with mental status disorder (delirium or abulia; OR = 4.59; 95% CI = 1.41-14.89) and negatively associated with headache (OR = 0.03; 95% CI = 0.00-0.32). Presentation as isolated intracranial hypertension was associated with admission delay of more than 4 days (OR = 2.63; 95% CI = 0.97-7.14). Papilloedema was associated with admission delay of more than 13 days (OR = 4.69; 95% CI = 161-13,61). As far as the infl uence of admission delay on treatment is concerned, there was no association between admission delay and the proportion of anticoagulated patients: 20 anticoagulated out of 22 patients admitted within 24 h (91%) vs. 55/68 admitted later (81%; p = 0.27); 34 anticoagulated out of 43 patients admitted within 4 days (79%) vs. 41/47 admitted later (87%; p = 0.30); 56 anticoagulated out of 68 admitted within 13 days (82%) vs. 19/22 (86%; p = 0.766) admitted later. The interval between onset of symptoms and start of anticoagulation was shorter for patients admitted earlier (p = 0.0001, median test, for either admission within 24 h, 4 or 13 days). However there were no differences in the interval between admission and start of anticoagulation between patients admitted within or after each of those time windows.
Discussion
In this cohort mean delay between onset of symptoms and hospital admission was 4 days, though with a wide variation range. Presentation as isolated intracranial hypertension and older age were associated with an increased delay in hospital admission. Not surprisingly, anticoagulation was started earlier in patients with early presentation, but the proportion of anticoagulated patients was not infl uenced by the admission delay. This is the fi rst systematic study to describe and analyse the admission delay of CVT patients; however, it has some limitations. The onset of symptoms in CVT can be gradual, the precise day of onset being diffi cult to defi ne and infl uenced by recall bias. After hospital admission it may take a few days to reach the diagnosis and this will further delay starting appropriate treatment. Unfortunately we did not record the day of the confi rmation of the diagnosis. However the delay in starting anticoagulation after admission was similar in all patients (independent of ultra-early, early or late admission). This is an indirect indication that the time to diagnosis after admission was not infl uenced by admission delay. We also did not collect information on medical encounters previous to hospital admission or on the patients' own view of their health problem.
A quarter of the patients were admitted on the day of symptoms onset and two thirds were admitted within a reasonable interval of 1 week. Only 15% entered hospital more than 3 weeks after the fi rst symptoms. Factors infl uencing early presentation can be related to the patient, the disease or the health care organisation; these three factors contribute to admission delays in CVT patients. The wide variation in admission delays refl ects the patients', their proxies' and physicians' diffi culties in recognising the seriousness of the condition. Presentation as isolated intracranial hypertension syndrome and older age were independent predictors of delayed admission. When experiencing a rather common symptom (such as headache), patients may delay seeking medical attention and physicians may be reluctant to order an MRI as fi rstline imaging procedure. The relative rarity of CVT makes it less likely to be included in the differential diagnosis list of a general practitioner or emergency physician examining a patient complaining of a headache. They probably do not perform fundoscopy routinely. The fi nding of papilloedema may trigger admission, but papilloedema may take days to develop. Conceivably, the need to perform MRI to confi rm the diagnosis delays the diagnosis of CVT because MRI is less readily available and more costly than CT.
Admission delay had no impact on the prescription of anticoagulants, although patients who came earlier also started treatment sooner. Breteau et al. [17] registered the delay (median 5 days) between onset of symptoms and starting heparin in a series of 55 CVT patients. Delay in starting heparin had an infl uence on outcome. In Einhäupl et al.'s [18] trial heparin was started a mean of 32.5 days after the initial symptoms, while in the nadroparin trial [19] the mean delay from symptoms onset to randomisation was 10 days. In a systematic review of thrombolysis in CVT [12] , the outcome of patients treated before and 1 week after onset was similar. In their series of 18 CVT patients Rondepierre et al. [20] also found no association between admission delay and diagnosis and outcome. This is in accordance with our previous fi nding that admission delay was not associated with a worse outcome [14, 15] . One factor contributing to this counterintuitive result is the very early admission of patients with more dramatic and severe clinical presentations who have a less favourable prognosis. Therefore there is currently no convincing evidence that delay in establishing the diagnosis or in starting treatment infl uences outcome.
The results of this investigation must be confi rmed in a larger sample, preferably multinational, to decrease local practice bias. This is particularly important for our fi nding that admission delay does not seem to impact on outcome. If possible, other factors should be investigated, including the intra-hospital delay in diagnosis and factors leading the patient to look for medical attention, medical contacts and diagnosis before CVT confi rmation.
Our results have some implications for practice. There is considerable delay in recognising that the clinical picture associated with CVT is serious enough to justify hospital admission. Headaches are the most frequent symptom of CVT, but CVT presenting as headache or intracranial hypertension syndrome is more diffi cult to diagnose. CVT should be considered a potential diagnosis in patients presenting new-onset headaches, or headaches of a type or severity different to their usual ones. Early recognition of CVT hastens commencement of appropriate treatment and also speeds the search for treatable, potentially health-threatening risk factors and associated conditions. At present, MRI must be performed to confi rm CVT. D-dimers can be used as a screening tool for CVT [21] , although there is a possibility of false negatives [22] . A sensible sequence to exclude CVT in patients presenting with headaches would be to perform CT and Ddimers in all patients and to request MR only for those with direct or indirect signs of CVT on CT and/or high D-dimers titers. It remains to be seen which strategy is more cost effective: using this diagnostic sequence or referring patients with such types of headaches directly for MRI to screen for CVT (and other intracranial diseases).
